Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) EBITDA (2019 - 2025)

Volitionrx filings provide 9 years of EBITDA readings, the most recent being -$6.2 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 10.05% to -$6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.2 million, a 10.81% increase, with the full-year FY2025 number at -$24.2 million, up 10.81% from a year prior.
  • EBITDA hit -$6.2 million in Q4 2025 for Volitionrx, down from -$5.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$5.4 million in Q3 2025 to a low of -$9.5 million in Q2 2023.
  • Median EBITDA over the past 5 years was -$7.5 million (2022), compared with a mean of -$7.3 million.
  • Biggest five-year swings in EBITDA: crashed 67.89% in 2021 and later skyrocketed 36.2% in 2024.
  • Volitionrx's EBITDA stood at -$8.8 million in 2021, then grew by 15.49% to -$7.4 million in 2022, then fell by 18.46% to -$8.8 million in 2023, then skyrocketed by 36.2% to -$5.6 million in 2024, then decreased by 10.05% to -$6.2 million in 2025.
  • The last three reported values for EBITDA were -$6.2 million (Q4 2025), -$5.4 million (Q3 2025), and -$6.9 million (Q2 2025) per Business Quant data.